Alaxia at North American Cystic Fibrosis Conference
Alaxia moves forward its promising CF antimicrobial drug candidate at the North American Cystic Fibrosis Conference from October 18th-20th in Denver.
On this occasion, Alaxia will present results on the “Post-antibiotic effect of OSCN-, lactoferrin and ALX-009 on clinical strains isolated from cystic fibrosis patients”. These exciting results confirm the interest of the ALX-009 combination to fight bacterial infections in CF patients.
To get more about Alaxia activities and its innovative First-in-Class orphan drug combination, ALX-009, you can visit the following website :